Skip to main content
logo

IntoCell, Inc. (KOSDAQ:287840)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,200
+1,280 (6.43%)
At close: Aug 11, 2026
Market Cap318.47B -14.9%
Revenue (ttm)2.47B -15.8%
Net Income-11.24B
EPS-765.46
Shares Out 15.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume64,227
Open20,000
Previous Close19,920
Day's Range19,470 - 21,400
52-Week Range13,050 - 74,900
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About IntoCell

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 287840
Full Company Profile

Financial Performance

In 2025, IntoCell's revenue was 2.30 billion, a decrease of -20.86% compared to the previous year's 2.91 billion. Losses were -10.60 billion, 6.97% more than in 2024.

Financial Statements